Unknown

Dataset Information

0

Development of an ?-synuclein knockdown peptide and evaluation of its efficacy in Parkinson's disease models.

ABSTRACT: Convincing evidence supports the premise that reducing ?-synuclein levels may be an effective therapy for Parkinson's disease (PD); however, there has been lack of a clinically applicable ?-synuclein reducing therapeutic strategy. This study was undertaken to develop a blood-brain barrier and plasma membrane-permeable ?-synuclein knockdown peptide, Tat-?syn-degron, that may have therapeutic potential. The peptide effectively reduced the level of ?-synuclein via proteasomal degradation both in cell cultures and in animals. Tat-?syn-degron decreased ?-synuclein aggregates and microglial activation in an ?-synuclein pre-formed fibril model of spreading synucleinopathy in transgenic mice overexpressing human A53T ?-synuclein. Moreover, Tat-?syn-degron reduced ?-synuclein levels and significantly decreased the parkinsonian toxin-induced neuronal damage and motor impairment in a mouse toxicity model of PD. These results show the promising efficacy of Tat-?syn-degron in two different animal models of PD and suggest its potential use as an effective PD therapeutic that directly targets the disease-causing process.

SUBMITTER: Jin JW 

PROVIDER: S-EPMC7895943 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Convincing evidence supports the premise that reducing α-synuclein levels may be an effective therapy for Parkinson's disease (PD); however, there has been lack of a clinically applicable α-synuclein reducing therapeutic strategy. This study was undertaken to develop a blood-brain barrier and plasma membrane-permeable α-synuclein knockdown peptide, Tat-βsyn-degron, that may have therapeutic potential. The peptide effectively reduced the level of α-synuclein via proteasomal degradation both in ce  ...[more]

Similar Datasets

Unknown Alpha-synuclein mutations impair axonal regeneration in models of Parkinson's disease.
| S-EPMC4159996 | biostudies-literature
Unknown Alpha-Synuclein Preformed Fibrils Induce Cellular Senescence in Parkinson's Disease Models.
| S-EPMC8304385 | biostudies-literature
Unknown Disrupting the α-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson's disease.
| S-EPMC10115881 | biostudies-literature
Unknown Alpha-synuclein and familial Parkinson's disease.
| S-EPMC3397145 | biostudies-literature
Unknown Alpha-Synuclein Aggregation in Parkinson's Disease.
| S-EPMC8558257 | biostudies-literature
Unknown Selective α-Synuclein Knockdown in Monoamine Neurons by Intranasal Oligonucleotide Delivery: Potential Therapy for Parkinson's Disease.
| S-EPMC5835151 | biostudies-literature
Unknown TREM2 deficiency aggravates α-synuclein-induced neurodegeneration and neuroinflammation in Parkinson's disease models.
| S-EPMC6902667 | biostudies-literature
Unknown Interaction between coxsackievirus B3 infection and α-synuclein in models of Parkinson's disease.
| S-EPMC8568191 | biostudies-literature
Unknown A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
| S-EPMC5840882 | biostudies-literature
Unknown Alpha-Synuclein mRNA Is Not Increased in Sporadic PD and Alpha-Synuclein Accumulation Does Not Block GDNF Signaling in Parkinson's Disease and Disease Models.
| S-EPMC5628770 | biostudies-literature